Superstring Capital Management’s UroGen Pharma URGN Stock Holding History

Superstring Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.04M	Sell	191,313 -196,058	-51%	-$5.31M	4.45%	10
2026 Q1	$6.96M	Sell	387,371 -330,983	-46%	-$6.64M	4.98%	5
2025 Q4	$16.8M	Buy	718,354 +630,442	+717%	+$13.7M	9.01%	3
2025 Q3	$1.75M	Hold	87,912	–	–	1.73%	23
2025 Q2	$1.2M	Sell	87,912 -335,720	-79%	-$3.22M	1.43%	23
2025 Q1	$4.69M	Buy	423,632 +122,426	+41%	+$1.31M	5.57%	6
2024 Q4	$3.21M	Buy	+301,206	New	+$3.61M	2.78%	10
2024 Q2	–	Sell	-288,267	Closed	-$4.32M	–	56
2024 Q1	$4.32M	Buy	288,267 +32,837	+13%	+$537K	2.86%	13
2023 Q4	$3.83M	Buy	+255,430	New	+$3.32M	2.73%	12

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Superstring Capital Management's URGN Position: Q2 2026 in Review

Superstring Capital Management reduced its UroGen Pharma (URGN) stake by 51% in Q2 2026, selling an estimated $5.31M and leaving 191,313 shares worth $7.04M. The position accounts for 4.45% of the portfolio, ranked #10.

Superstring Capital Management first reported a position in URGN in Q4 2023 and has held it in 9 quarters since. The position peaked at $16.8M in Q4 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Superstring Capital Management held 191,313 shares of UroGen Pharma worth $7.04M as of Q2 2026.
Superstring Capital Management sold 196,058 UroGen Pharma shares in Q2 2026, an estimated $5.31M.
UroGen Pharma made up 4.45% of Superstring Capital Management's portfolio in Q2 2026, its #10 holding.
Superstring Capital Management first reported a position in UroGen Pharma in Q4 2023 and has held it in 9 quarters since.
Superstring Capital Management's UroGen Pharma position peaked at $16.8M in Q4 2025.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.